Latest Conference Articles

Sharing, learning, networking, collaborating

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

Moon Jeong Lee, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Ophthalmology during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Marta Stevanovic, MD, Massachusetts Eye and Ear, Harvard Medical School, Boston, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Retina during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Analisa Arosemena, MD, underscores the importance of year-round glaucoma control through extended-release medications and laser treatments at EyeCon 2023.

Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.

Jennifer Loh, MD, discusses the significance of maintaining a healthy ocular surface before surgery and exploring collaborative approaches for improved patient comanagement between ophthalmologists and optometrists at EyeCon 2023.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept at this year's American Academy of Ophthalmology meeting.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with Ophthalmology Times about the GALE study data at one year looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Mariam Maghribi, Chief Business Officer for Shifamed, spoke with Ophthalmology Times about the Atia Vision IOL device at this year's American Academy of Ophthalmology meeting.

Nick Curtis, CEO at LENSAR, met with Ophthalmology Times to discuss their co-development with Oertli on their phaco device and LENSAR's Ally treatment system at the American Academy of Ophthalmology.

Rick Lewis, MD, Chief Medical Officer for ViaLase met with Ophthalmology Times to discuss completion of their important pivotal trial called VIA-002, which is a randomized prospective trial of the use of the ViaLase Laser versus SLT in adult patients with primary open angle glaucoma at the American Academy of Ophthalmology.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Clara Chan, MD, FRSCS, FACS, DABO, from the University of Toronto spoke with Ophthalmology Times about their study on the consistency of outcomes across 3 different cohorts of patients that were internationally collected at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Swarup Swaminathan, MD, spoke with Ophthalmology Times about using the Heidelberg SPECTRALIS and caring for our Glaucoma patients at this year's American Academy of Ophthalmology meeting.

Daniel Chang, MD, spoke with Ophthalmology Times about his poster "Clinical performance of a diffractive, extended depth-of-focus IOL, with violet light filtering and high-resolution lathing" at this year's American Academy of Ophthalmology meeting.

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

First-in-human feasibility study.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

Ben Bergo, CEO of Visus Therapeutics spoke with Ophthalmology Times about the study on presbyopia, BRIO-I at this year's American Academy of Ophthalmology meeting.